Sanofi, the French pharmaceutical company, is reportedly planning a substantial investment in Frankfurt, Germany. The company is said to be considering investing between 1.3 and 1.5 billion euros in its insulin production in the Hochst district. This investment would involve the construction of a new production facility, replacing the existing one with more modern technology.
Although a final decision has not been reached, preparations for the construction work in Hochst are said to be already underway. The potential investment has garnered positive reactions from key figures, including German Chancellor Olaf Scholz and the Hessian state government.
Chancellor Scholz expressed his satisfaction with the news, while the Hessian state government indicated a willingness to support the initiative financially to safeguard and create jobs, drive investments, and foster innovation.
The news of Sanofi’s possible investment comes at a crucial time for Germany, amidst concerns over the country’s business environment and the availability of essential medicines. The pharmaceutical industry in Germany has recently seen commitments from various foreign companies, such as Eli Lilly, Daiichi-Sankyo, Roche, and Merck, to invest billions in the country.
While Sanofi has not officially confirmed the investment plans, the company stated that it is consistently exploring opportunities to enhance its global supply chains and ensure the availability of critical medications and vaccines for patients.
